T2610 |
BMS-599626
|
714971-09-2
|
98.73%
|
|
BMS-599626 has been used in trials studying the treatment of Cancer, Metastases, and HER2 or EGFR Expressing Advanced Solid Malignancies.
|
T10583 |
Bosutinib D8
|
T10583
|
98%
|
|
Bosutinib D8 is a deuterium-labeled Bosutinib. Bosutinib (SKI-606) is a dual Src/Abl inhibitor (IC50s: 1.2 nM/1 nM).
|
T14074 |
A-770041
|
869748-10-7
|
98%
|
|
A-770041 is selective and orally active Src-family Lck inhibitor, and the other Src family kinase involved in T-cell signaling. A-770041 is a 147 nM inhibitor of...
|
T11752 |
Keap1-Nrf2-IN-1
|
2232112-72-8
|
98%
|
|
Keap1–Nrf2 IN-1 activates Nrf2-regulated cytoprotective response and antagonizes acetaminophen-induced liver injury both in cellular and in vivo models. Keap1–Nr...
|
T10784 |
CH6953755
|
2055918-71-1
|
98%
|
|
CH6953755 is a potent, orally active and selective inhibitor of YES1 kinase (IC50: 1.8 nM). It inhibits YES1 kinase, leading to antitumor activity against YES1 G...
|
T10206 |
A 419259
|
364042-47-7
|
98%
|
|
A 419259 is a pyrrolo-pyrimidine inhibitor, designed to enhance selectivity towards the Src family (IC50s: 9 nM, <3 nM and <3 nM for Src, Lck and Lyn).
|
TN3139 |
5α-Hydroxycostic acid
|
132185-83-2
|
98%
|
|
5alpha-Hydroxycostic acid possesses anti-angiogenic ability by interfering the VEGF- and Ang2-related pathways, and it may be a good drug candidate.
|
T15674 |
Tirbanibulin dihydrochloride
|
1038395-65-1
|
98%
|
|
Tirbanibulin is an inhibitor of Src that targets the peptide substrate site of Src (GI50: 9-60 nM in cancer cell lines).
|
T14055 |
5Z-7-Oxozeaenol
|
253863-19-3
|
98%
|
|
5Z-7-Oxozeaenol, a natural anti-protozoan compound from fungal origin, acting as a potent irreversible and selective inhibitor of TAK1 and VEGF-R2, with IC50s of...
|
T13186L |
TL02-59 dihydrochloride
|
2415263-06-6
|
98%
|
|
TL02-59 dihydrochloride is an orally active inhibitor of Src-family kinase Fgr (IC50: 0.03 nM).
|
T22303 |
Dasatinib hydrochloride
|
854001-07-3
|
99.98%
|
|
Dasatinib hydrochloride (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. ...
|
T4301 |
AD80
|
1384071-99-1
|
99.9%
|
|
AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.
|
T1448 |
Dasatinib
|
302962-49-8
|
99.89%
|
|
Dasatinib is a potent inhibitor of the Bcr-Abl and Src family (IC50s: 0.6, 0.8, 79 and 37 nM for Abl, Src, c-Kit, and c-KitD816V, respectively).
|
T2341 |
KW-2449
|
1000669-72-6
|
99.89%
|
|
KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 (IC50: 6.6 nM), modestly effective to Bcr-Abl, FGFR1, and Aurora A; little inhibitory on PDGFRβ, IGF-1R...
|
T6680 |
Staurosporine
|
62996-74-1
|
99.87%
|
|
Staurosporine is a potent PKC inhibitor for PKCα/γ/η (IC50: 2/5/4 nM), less potent to PKCε (73 nM), PKCδ (20 nM) and little action to PKCζ (1086 nM).
|
T2327 |
Pelitinib
|
257933-82-7
|
99.86%
|
|
Pelitinib (EKB-569) is an effective irreversible EGFR inhibitor (IC50: 38.5 nM).
|
T4071 |
Repotrectinib
|
1802220-02-5
|
99.86%
|
|
TPX-0005 is a potent ALK/ROS1/TRK inhibitor, with IC50 of 1.01 nM, 5.3 nM, 1.08 nM and 1.26 nM for WT ALK, SRC, ALK L1196M and ALK G1202R, respectively.
|
T3935 |
1-Naphthyl PP1
|
221243-82-9
|
99.85%
|
|
1-Naphthyl PP1 is a selective src inhibitor(v-Src and c-Fyn, c-Abl, CDK2 and CAMK II with IC50s of 1.0, 0.6, 0.6, 18 and 22 μM, respectively)
|
T0152 |
Bosutinib
|
380843-75-4
|
99.84%
|
|
Bosutinib is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: 1 nM) and Src (IC50: 1.2 nM) kinases.
|
T2640 |
Rebastinib
|
1020172-07-9
|
99.84%
|
|
DCC-2036 (Rebastinib) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC, HCK, FGR, FLT...
|